Pre-made Loncastuximab benchmark antibody ( Whole mAb ADC, anti-CD19 therapeutic antibody, Anti-B4/CVID3 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Loncastuximab biosimilar, Whole mAb ADC, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Loncastuximab tesirine is an antibody-drug conjugate designed to target human CD19. It is a humanized monoclonal antibody and conjugated to SG3199, a pyrrolobenzodiazepine (PBD) dimer cytotoxin by a protease enzyme cleavable valine-alanine linker.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-320-1mg	1mg	Inquiry
GMP-Bios-ab-320-10mg	10mg	Inquiry
GMP-Bios-ab-320-100mg	100mg	Inquiry
GMP-Bios-ab-320-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Loncastuximab biosimilar, Whole mAb ADC, Anti-CD19 Antibody: Anti-B4/CVID3 therapeutic antibody
INN Name	Loncastuximab
Target	CD19
Format	Whole mAb ADC
Derivation	Chimeric (Mouse/Human)
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	None
99% SI Structure	6ani:HL:IM
95-98% SI Structure	None
Year Proposed	2017
Year Recommended	2018
Companies	ADC Therapeutics
Conditions Approved	Diffuse large B cell lymphoma
Conditions Active	Follicular lymphoma;Mantle-cell lymphoma;Non-Hodgkin's lymphoma
Conditions Discontinued	Precursor B-cell lymphoblastic leukaemia-lymphoma
Development Tech	na